Table 7 Modulable options of the portfolio Monte Carlo simulation model

Total number of drugs in portfolio

8

Number of drugs starting in preclinical in year 0

8

Number of me-too drugs that are a follow-on of successful drugs in phase 2

0

Number of drugs starting in phase 2 in year 0

0

Correlation of time and cost of development for phases 2 and 3 for the copula within each drug

0.5

Correlation of PoS for the normal copula across drugs for the same phase

0.2

Correlation of commercial value for the normal copula across drugs for the same phase

0.2